Temodal, also known by its generic name temozolomide, is a type of chemotherapy medication used primarily in the treatment of certain brain cancers, including glioblastoma multiforme and anaplastic astrocytoma. It belongs to a class of drugs known as alkylating agents, which work by damaging the DNA of cancer cells, thereby inhibiting their ability to reproduce and grow. Temodal is administered orally in capsule form or through intravenous injection, depending on the specific needs and condition of the patient. Its use is often associated with a range of side effects, which can include nausea, vomiting, fatigue, and a decrease in blood cell counts, among others. Despite these side effects, Temodal plays a crucial role in the management and treatment of malignant brain tumors, offering hope and extending survival for many patients facing these challenging diagnoses.